Thomas Chalopin
Impact in
- Hematology top 5%
- Multiple Myeloma Research and Treatments
- Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment
Papers in
- Hematology 26
- Multiple Myeloma Research and Treatments 25
- Oncology 11
- Peptidase Inhibition and Analysis 7
- Cancer Treatment and Pharmacology 4
- Co-authors
- Olivier Hérault (6 shared papers)Nicolas Vallet (6 shared papers)Emmanuel Gyan (6 shared papers)Adrien Lemaignen (2 shared papers)Lotfi Benboubker (3 shared papers)Louis Bernard (2 shared papers)Julien Lejeune (1 shared paper)Carole Barin (2 shared papers)
In The Last Decade
Thomas Chalopin
28 papers receiving 412 citations
Thomas Chalopin's Hit Papers
Peers
Comparison fields: 5 of 39
- Hematology 214
- Pathology and Forensic Medicine 118
- Oncology 153
- Dermatology 37
- Immunology 54
Countries citing papers authored by Thomas Chalopin
This map shows the geographic impact of Thomas Chalopin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Chalopin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Chalopin more than expected).
Fields of papers citing papers by Thomas Chalopin
This network shows the impact of papers produced by Thomas Chalopin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Chalopin. The network helps show where Thomas Chalopin may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Chalopin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 118 | |
| 2 | 2024 | 65 | |
| 3 | 2024 | 43 | |
| 4 | Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma Hit paper breakdown → | 2025 | 30 |
| 5 | 2023 | 22 | |
| 6 | 2025 | 16 | |
| 7 | 2022 | 13 | |
| 8 | 2019 | 10 | |
| 9 | 2024 | 10 | |
| 10 | 2024 | 10 | |
| 11 | 2021 | 9 | |
| 12 | 2024 | 9 | |
| 13 | 2020 | 9 | |
| 14 | 2020 | 7 | |
| 15 | 2023 | 7 | |
| 16 | 2021 | 7 | |
| 17 | 2018 | 7 | |
| 18 | 2017 | 5 | |
| 19 | 2024 | 5 | |
| 20 | 2023 | 4 |
About Thomas Chalopin
Thomas Chalopin is a scholar working on Hematology, Oncology, Molecular Biology, Pathology and Forensic Medicine and Genetics, having authored 35 papers that have together received 420 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (8 papers), Peptidase Inhibition and Analysis (7 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (5 papers), Cancer Treatment and Pharmacology (4 papers), Lymphoma Diagnosis and Treatment (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Cancer therapeutics and mechanisms (3 papers). The work is most often cited by research in Hematology (214 citations), Pathology and Forensic Medicine (118 citations), Oncology (153 citations), Dermatology (37 citations) and Immunology (54 citations). Thomas Chalopin has collaborated with scholars based in France, Belgium and Poland. Frequent co-authors include Olivier Hérault, Nicolas Vallet, Emmanuel Gyan, Adrien Lemaignen, Lotfi Benboubker, Louis Bernard, Julien Lejeune, Carole Barin, Louise A. Barbier and Marion Morel. Their work appears in journals such as Blood, Blood Cancer Journal, BMC Infectious Diseases, British Journal of Haematology and HemaSphere.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.